• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Helsinn Group presents phase III data in NEPA at MASCC/ISOO Congress

Helsinn Group presents phase III data in NEPA at MASCC/ISOO Congress

June 21, 2017
CenterWatch Staff

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, has announced that data showing the non-inferiority of NEPA (netupitant/palonestron) versus a 3-day oral aprepitant (APR)/granisetron (GRAN) regimen, have been accepted for presentation at the upcoming Multinational Association of Supportive Care in Cancer (MASCC/ISOO) Congress, on June 22-24 2017.

NEPA is the first fixed combination of the selective NK1RA, netupitant (300 mg), and the clinically and pharmacologically active 5-HT3RA, palonosetron (0.5mg) for the prevention of CINV, in a convenient single capsule.

This randomized, double-blind, Phase 3 study conducted in 828 chemotherapy-naïve Asian patients receiving cisplatin-based emetogenic chemotherapy (HEC) agents, is the first head to head study comparing NK1RA regimens. Patients received a single oral dose of NEPA on day 1 or a 3-day oral APR/GRAN regimen (days 1-3). All patients received oral dexamethasone on days 1-4. The primary efficacy endpoint was complete response (CR: no emesis/rescue medication) during the overall (0-120h) phase. Non-inferiority was defined as a lower 95% CI greater than the non-inferiority margin set at -10%. Secondary endpoints included no emesis no rescue medication and no significant nausea (NSN: <25mm on 100mm VAS).

For the primary efficacy endpoint of overall CR, NEPA on day 1 was non-inferior to 3-day oral APR/GRAN regimen with a comparable safety profile. In addition the daily CINV events (emesis and/or rescue medication use) declined numerically over time with NEPA reaching the statistical significance at day 5 compared to APR/GRAN arm suggesting a benefit for delayed CINV.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing